Nurix Therapeutics to Host Webcast on December 8 to Review BTK Degrader Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Should l Buy NRIX?
Source: Globenewswire
- Clinical Data Update: Nurix Therapeutics will host a webcast on December 8, 2025, to present updated clinical data on its BTK degrader, bexobrutideg, aiming to enhance investor understanding of the company's R&D progress and bolster market confidence.
- Expert Participation: The webcast will feature guest speaker Dr. Alvaro Alencar from the University of Miami Sylvester Cancer Center, who will share clinical trial data on bexobrutideg in patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia, further validating the drug's clinical efficacy.
- Clinical Trial Progress: Bexobrutideg is currently undergoing the NX-5948-301 Phase 1a/1b clinical trial, evaluating its efficacy in patients with relapsed or refractory B-cell malignancies, which is expected to provide critical data support for the company's future drug development.
- Corporate Strategy Update: Nurix's CEO Arthur T. Sands and CMO Paula G. O’Connor will discuss the company's clinical development strategy during the webcast, showcasing its innovative capabilities in targeted protein degradation, aiming to attract more investor interest in its potential market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRIX
Wall Street analysts forecast NRIX stock price to rise
16 Analyst Rating
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.730
Low
12.00
Averages
28.93
High
41.00
Current: 15.730
Low
12.00
Averages
28.93
High
41.00
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
Evercore ISI Upgrades Roku to Outperform, Raises Price Target to $145
- Positive Catalysts: Evercore ISI upgrades Roku from In Line to Outperform, raising its price target from $105 to $145, reflecting optimism about the company's future growth potential.
- Buying Opportunity: Bank of America upgrades Coinbase from Neutral to Buy, believing that despite a 40% drop from July highs, the company's increased product velocity and expanded market size will drive future growth.
- Transformation Signal: UBS initiates coverage of Bread Financial with a Buy rating and a $92 price target, indicating that the company is approaching the next phase of its turnaround, which may attract more investor interest.
- Market Challenges: Needham downgrades Nike to Hold, citing slow progress in its turnaround and concerns over the recent sell-in levels to the North American wholesale channel, with expectations for the next 12-24 months appearing too high.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, reflecting the rapid rise of precision therapies and immunotherapies, enhancing the investment outlook for companies like GT Biopharma.
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients receive a dosing of 10μg/kg/day, indicating potential efficacy in treating resistant blood cancers and providing new treatment options for patients.
- Safety Confirmation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing its safety profile with no dose-limiting toxicities observed across all completed cohorts, thereby boosting confidence in the clinical trial.
- Future Outlook: GT Biopharma plans to share its next trial update in Q1 2026, with expectations to continue assessing higher doses for efficacy, further driving innovation in the field of tumor immunotherapy.
See More
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
Evercore ISI Upgrades Roku to Outperform, Raises Price Target to $145
- Positive Catalysts: Evercore ISI upgrades Roku from In Line to Outperform, raising its price target from $105 to $145, reflecting optimism about the company's future growth potential.
- Buying Opportunity: Bank of America upgrades Coinbase from Neutral to Buy, believing that despite a 40% drop from July highs, the company's increased product velocity and expanded market size will drive future growth.
- Transformation Signal: UBS initiates coverage of Bread Financial with a Buy rating and a $92 price target, indicating that the company is approaching the next phase of its turnaround, which may attract more investor interest.
- Market Challenges: Needham downgrades Nike to Hold, citing slow progress in its turnaround and concerns over the recent sell-in levels to the North American wholesale channel, with expectations for the next 12-24 months appearing too high.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, reflecting the rapid rise of precision therapies and immunotherapies, enhancing the investment outlook for companies like GT Biopharma.
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients receive a dosing of 10μg/kg/day, indicating potential efficacy in treating resistant blood cancers and providing new treatment options for patients.
- Safety Confirmation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing its safety profile with no dose-limiting toxicities observed across all completed cohorts, thereby boosting confidence in the clinical trial.
- Future Outlook: GT Biopharma plans to share its next trial update in Q1 2026, with expectations to continue assessing higher doses for efficacy, further driving innovation in the field of tumor immunotherapy.
See More
